Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma
-
E. Almagro-Casado [1] ; A. Sánchez [1] ; B. Cantos [1] ; C. Salas [1] ; D. Pérez-Callejo [1] ; M. Provencio [1]
-
[1] Hospital Universitario Puerta de Hierro
Hospital Universitario Puerta de Hierro
Madrid, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 1, 2016, págs. 99-106
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose To evaluate the risk factors associated with lung cancer (LC) and other second neoplasms (SN) in Hodgkin lymphoma (HL) survivors.
Methods We retrospectively analyzed the clinical characteristics and outcomes of 604 patients treated in our institution between 1968 and 2012.
Results 90 out of 604 patients developed SN: 27 LC and 63 other SN. The median time elapsed until LC and other SN was 16.5 and 11.8 years, respectively (p = 0.003). In the LC group, 85.5 % of patients were male and 84.6 % smokers (HR 7, 95 % CI 2.4–20.7, p < 0.001). Radiotherapy (RT) doses applied were higher in the SN group with an increased risk of LC (HR: 4.0 95 % CI 1.1–11.6, p = 0.010) and other SN (HR: 3.3 95 % CI 1.6–6.7 p = 0.001) with doses higher than 42 Gy. No association was found between alkylating agents and development of SN. In LC, the most frequent histology was adenocarcinoma with an elapsed time after HL of 13.2 years in early stages and 21.3 in advanced (p = 0.02). Median OS after a diagnosis of LC was 12.6 months ranging from 5.9 (in cases presenting due to symptoms) to 49.1 (incidentally diagnosed cases) (p = 0.005).
Conclusions RT treatment, especially with doses higher than 42 Gy, and smoking increase the risk of SN after HL. In this series, LC patients with early stages had a shorter elapsed time from HL diagnosis and longer OS, therefore the role of LC screening in HL survivors should be prospectively evaluated and smoking cessation counseling ought to be a key aspect during follow-up.
